bullish

Amgen Inc

Amgen Faces A Biosimilar Tipping Point: Can New Products Outrun Prolia & XGEVA Erosion?

98 Views21 Aug 2026 22:01
Amgen reported robust second-quarter performance driven by a diversified portfolio and key growth drivers that collectively grew 26%...
What is covered in the Full Insight:
  • Introduction
  • Amgen's Diversified Portfolio Performance
  • Pipeline Progress and Future Prospects
  • Valuation Methodology and Analysis
  • Conclusion and Investor Insights
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 47-minute read)
Discussions
(Paid Plans Only)
chart-bar
Price Chart(Sign Up to Access)
analytics-chart
  • Amgen Faces A Biosimilar Tipping Point: Can New Products Outrun Prolia & XGEVA Erosion?
    21 Aug 2026
x